Dewpoint Therapeutics has entered a strategic partnership with Evotec to progress the research and development of its oncology pipeline programmes comprising condensate modifying therapeutics (c-mods).

The c-mods will be advanced to the investigational new drug application (IND) stage leveraging INDiGO, a wholly integrated data-driven platform of Evotec.

Dewpoint’s oncology pipeline programmes were discovered using its condensate biology and artificial intelligence technology platform to detect biomolecular condensate modulators. 

C-mods could offer new treatment options for complex ailments and targets that were previously undruggable.

Using Evotec’s expertise, the pre-clinical development candidates in Dewpoint’s pipeline will be de-risked and expedited to clinical trials in humans.

The deal will facilitate Dewpoint in expanding its capital efficiency while reducing risks. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dewpoint’s agreement is based on a risk-sharing approach under which Evotec is entitled to receive milestone and royalty payments contingent on the programmes’ success.

Dewpoint Therapeutics CEO Ameet Nathwani stated: “Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic. 

“Evotec’s integrated state-of-the-art operational technologies have been proven to deliver high-quality INDs across the industry. 

“A strategic relationship of this nature significantly enhances our development capabilities which can be transformative for a company at our stage of development, and we are delighted to have been able to forge this partnership with a leader like Evotec.”

In September 2023, Dewpoint and Chemify partnered to accelerate the discovery of molecules to treat cancer and neurodegeneration.

This content was updated on 25 January 2024